Top
image credit: Adobe Stock

Psychedelic clinical trials: What sponsors should know when designing new protocols

Psychedelic products are having a renaissance moment.

As evidence emerges about their potential for PTSD, depression, cancer-related distress and more, the market for psychedelics could swell from $2 billion in 2020 to $10.75 billion in 2027. With regulators and lawmakers seemingly on board, sponsors have more opportunities than ever to pursue clinical research in this high-velocity area.

“Everywhere you turn, there’s some news piece about it,” said Christine Moore, Ph.D., Vice President of Scientific Solutions, Neuroscience, at Worldwide Clinical Trials. “It’s not too surprising given the mental health crisis. We have a huge unmet need, so there’s a lot of enthusiasm about the potential of these products.”

Read More on Biopharma Dive